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Protocol
AbstrACt
Introduction Following growing evidence to support the 
safety, local control (LC) and potential improvement in 
overall survival (OS) in patients with oligometastatic non-
small cell lung cancer (NSCLC) that have been treated 
with local ablative therapy such as stereotactic ablative 
radiotherapy (SABR) and stereotactic radiosurgery (SRS), 
we initiate the SARON trial to investigate the impact and 
feasibility of adding SABR/SRS and radical radiotherapy 
(RRT) following standard chemotherapy on OS.
Methods and analysis SARON is a large, randomised 
controlled, multicentre, phase III trial for patients with 
oligometastatic EGFR, ALK and ROS1 mutation negative 
NSCLC (1–3 sites of synchronous metastatic disease, 
one of which must be extracranial). 340 patients will be 
recruited over 3 years from approximately 30 UK sites 
and randomised to receive either standard platinum-
doublet chemotherapy only (control arm) or standard 
chemotherapy followed by RRT/SABR to their primary 
tumour and then SABR/SRS to all other metastatic sites 
(investigational arm). The primary endpoint is OS; the 
study is powered to detect an improvement in median 
survival from 9.9 months in the control arm to 14.3 
months in the investigational arm with 85% power and 
two-sided 5% significance level. The secondary endpoints 
are LC, progression-free survival, new distant metastasis-
free survival, toxicity and quality of life. An early feasibility 
review will take place after 50 randomised patients. 
Patients requiring both conventional thoracic RT to the 
primary and SABR to a thoracic metastasis will be included 
in a thoracic SABR safety substudy to assess toxicity 
and planning issues in this subgroup of patients more 
thoroughly.
Ethics and dissemination All participants are given a 
SARON patient information sheet and required to give 
written informed consent. Results will be submitted for 
presentation at local and international conferences and 
expected to be published in a peer-reviewed journal.
trial registration number NCT02417662.
sponsor reference UCL/13/0594.
bACkground
oligometastatic nsCLC 
Unselected European patients with oligomet-
astatic non-small cell lung cancer (NSCLC) 
treated with cytotoxic chemotherapy have a 
median survival of 8.5–10.5 months.1 2 This 
figure includes patients with any number of 
metastases. There are increasing data though 
strengths and limitations of this study
 ► SARON is a large, randomised  controlled, multi-
centre, UK phase III trial.
 ► 340 patients will be recruited over 3 years from ap-
proximately 30 UK sites.
 ► The trials primary endpoint is overall survival and 
is powered to detect an improvement in median 
survival from 9.9 months in the control arm to 14.3 
months in the experimental arm.
 ► Patients requiring both conventional thoracic ra-
diotherapy to the primary and stereotactic ablative 
radiotherapy (SABR) to a thoracic metastasis will be 
included in a thoracic SABR safety substudy to as-
sess toxicity and planning issues in this unique and 
challenging subgroup of patients more thoroughly.
 ► The trial will undergo an early feasibility review after 
50 randomised patients to ensure full recruitment is 
likely to be achievable.
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showing that patients with fewer sites of metastases seem 
to have a better overall survival (OS).
The MD Anderson group reported a retrospective review 
of outcomes in 1284 patients with metastatic NSCLC.3 It 
reported that patients with a single organ involved site 
had better OS than those with two or more. In 137 patients 
with lung metastases only, the risk of death was correlated 
with the number of metastases. Another study, the FLEX 
study, enrolled 1125 patients with metastatic NSCLC and 
reported similar OS benefit in patients with metastases in 
one site versus two sites versus three or more sites (12.4 
months vs 9.8 months vs 6.4 months, p<0.001).4 Similarly, 
the Southwest Oncology Group published an analysis of 
prognostic factors in 2531 patients enrolled in 14 phase 
II–III trials.5 The results confirm the prognostic signifi-
cance of single versus multiple metastases on multivariate 
analysis. These studies support the hypothesis that a lower 
tumour burden is associated with improved outcome.
The concept of oligometastatic disease was established 
in an editorial by Hellman and Weichselbaum.6 In it, 
they described that patients with a lower tumour burden 
might be candidates for a more radical approach to 
management. The key issues needed were the definitive 
demonstration that alternative treatment strategies would 
improve patient outcomes and the ability to prospectively 
identify patients with the least propensity to develop 
further systemic metastases.
Existing knowledge
Numerous retrospective studies7 have been published 
establishing the safety and efficacy of stereotactic ablative 
radiotherapy (SABR)/stereotactic radiosurgery (SRS) in 
achieving durable local control (LC) in many different 
single and multiorgan sites (lung,8 spine,9 liver,10–12 lymph 
nodes,13–15 adrenal glands,16 17 multiple metastases in indi-
vidual organs (liver,10–12 lung18 19 or multiple organs19 20).
In metastatic NSCLC, approximately 44% of patients 
will have brain metastases at first diagnosis.21 There is 
now evidence to suggest though that aggressive Central 
Nervous System directed treatment improves progres-
sion-free survival (PFS) and/or OS in some patients.22
Table 1 summarises the results of some of these SABR/
SRS studies and highlights the 1-year and 2-year control 
rates and low incidence of grade 3+ toxicities seen so far 
in the literature.
A few prospective studies have also been reported. De 
Ruysscher et al reported a single-arm phase II trial investi-
gating whether it would be possible to obtain a significant 
2-year and 3-year survival in patients when all macroscopic 
sites in oligometastatic NSCLC are treated with radical 
RT.21 The median OS was 13.5 months and PFS was 12.1 
months. In comparison, PFS in systemic therapy-only 
trials is reported to be around 4–6 months.1 Interestingly, 
the 2-year and 3-year PFS were maintained at 13.6%.
Another report is by Holy et al,16 treating patients with 
NSCLC and adrenal metastases. Median PFS was 4.2 
months for the entire patient group, but in those with 
isolated adrenal metastases, the PFS was 12 months. At 
21 months median follow-up, 10 of 13 patients (77%) 
with an isolated adrenal metastasis maintained LC with a 
median OS of 23 months.
Recently, Gomez and colleagues published the first, 
randomised trial supporting the first point made by 
Hellman and Weichselbaum.8 23 The trial was a phase II, 
multicentre study which randomised patients with NSCLC 
with oligometastatic disease (defined as ≤3 metastases) 
who did not progress after first line systemic treatment to 
either local consolidative therapy to all metastases, with or 
without systemic therapy or to standard systemic therapy 
alone. Local consolidative treatments included surgery, 
RT, chemo-RT or a combination thereof. The study was 
closed early after 49 patients were enrolled, as interim 
analysis found the median PFS in the local consolida-
tive therapy arm to be 14.4 months compared with 3.9 
months in the standard systemic therapy arm.23 Median 
OS was not reached. Recently, another phase II trial was 
reported by Texas Southwestern Medical Centre.24 They 
enrolled 29 patients with similar enrolment criteria, 
but their study design allowed for ≤6 sites of metastatic 
disease. The study was stopped early as interim analysis 
showed a significant PFS advantage in the SABR arm (9.7 
vs 3.5 months). SABR resulted in no in-field failure vs 
seven in the maintenance only arm. No additional toxic 
effect was noted in the SABR arm and median OS was also 
not reached.
There are several ongoing trials, either recruiting or 
in planning, such as ROLE (NCT01796288) and CORE 
(NCT02759783) that could support the role of radical 
radiotherapy (RRT)/SABR in oligometastatic disease 
further.
need for a trial
Currently there is no internationally agreed management 
strategy of oligometastatic NSCLC. Management recom-
mendations are thus widely variable and depend on local 
and patient-specific factors.
A large randomised phase III trial specific to NSCLC 
is therefore needed to ascertain if the addition of RRT 
with SABR/SRS or conventional radiotherapy to chemo-
therapy is safe and effective in improving the outcomes of 
patients with oligometastasis.
Choice of comparator
Without the ability to predict lack of systemic progres-
sion, the standard first-line management for patients with 
oligometastatic NSCLC remains to be chemotherapy.
In the SARON trial, the control arm will therefore be 
four cycles of platinum-based doublet chemotherapy 
followed by maintenance systemic therapy as per local 
policy. The type and dose regimen of chemotherapy 
given will be based on institution protocols.
Patients with sensitising EGFR, ALK-fusion and ROS1 
mutations have a different natural history and outcome 
to those without.33 To maintain as homogeneous a popu-
lation as possible, these patients are excluded from 
SARON.
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study objECtIvEs And hypothEsIs
study hypothesis
We propose that radical treatment with SRS/SABR or 
conventional radiotherapy to the primary lung and meta-
static lesions is safe, feasible and effective in improving 
the survival outcomes of oligometastatic NSCLC that 
have responded to initial treatment with systemic 
chemotherapy.
primary objective
To investigate the impact the addition RRT using SABR/
SRS or conventional RT has on OS in oligometastatic 
NSCLC that are treated with first-line standard systemic 
therapy.
secondary objectives
To demonstrate the impact of a RRT strategy on:
 ► Progression-free survival
 – Includes loss of LC of target lesions and develop-
ment of new distant metastases which will be re-
corded separately.
 – Also includes non-measurable radiological 
progression.
 ► Toxicity
 – RT-related toxicity.
 – Early and late toxicity.
 ► LC of primary and all metastases (refers to all lesions 
present at time of randomisation. A record will be 
kept of primary versus metastatic progression)
 ► Quality of life
Feasibility substudy
To demonstrate that the recruitment and withdrawal 
rates are consistent with achieving the aims of the trial 
and that there are no unforeseen logistical challenges 
Table 1 Summary of referenced studies of SABR in the treatment of oligometastatic disease
Reference
No. of
patients/lesions Primary
Site(s) of
metastases Dose/Fractions
Gd3+
toxicity
Local control
1 year 2 year
Rusthoven et al, 200925 38/63 Multiple colorectal Ca 
24%; sarcoma 18%; 
renal cell Ca  18%; lung 
13%
Lung 48–60 Gy/3# 7% 100% 96%
Ernst-Stecken et al, 
200626
21/39 Multiple lung* 43% Lung 35–40 Gy/5# 5%
Siva 20108
Review of 19 papers8 19
334/564 Multiple Lung 2.6%
4%
78%
Herfarth et al, 200127 37/60 Multiple Liver 14–26 Gy/1# 0% 71%
Mendez Romero 200612 17/34 Multiple
colorectal Ca 82%
Liver 36–60 Gy/3# 24% 100% 86%
Rusthoven et al, 200928 47/63 Multiple colorectal Ca 
32%; lung  21%
Liver 36–60 Gy/3# 2% 95% 92%
Lee et al, 200910 70/143 Multiple
CRC 57%
Liver 54–60 Gy/6# 10% 71%
Holy et al, 201116 18/18 NSCLC Adrenal 20–40 Gy/5# 77%†
Chawla et al, 200929 30/35 Multiple
NSCLC 67%
Adrenal 16–50 Gy/4–16#
Hoyer et al, 200630 64/142 Colorectal Ca Multiple liver 69%; 
lung 19%
45 Gy/3# 79%
Milano et al, 200831 121/293 Multiple breast  32%; 
colorectal Ca 26%
Multiple liver 45%; 
lung 41%;
thoracic nodes 
20%; bone 12%
50 Gy/5# <1% 67%
Salama et al, 201120 61/113 Multiple NSCLC 18%; 
breast 11%;
renal cell Ca  13%; 
colorectal Ca 10%
Multiple lung 36%; 
nodes 19%; liver 
19%; bone 13%
24–48 Gy/3# 13% 67% 53%
Gerszten et al, 20069 77/87 Lung Spine 15–25 Gy/1# 0%
Gerszten et al, 20059 28/36 Melanoma Spine 17.5–25Gy/1# 0%
Stinauer et al, 201132 17/28
13/25
Melanoma
Renal cell Ca
Multiple lung 74%; 
liver 21%
40–50 Gy/5# or
42–60 Gy/3#
2% 88%‡
*These were primary lung cancers.
†At a median follow-up of 21 months.
‡At 18 months.
NSCLC, non-small cell lung cancer; SABR, stereotactic ablative radiotherapy.
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which would prevent achieving full recruitment within 
the timescales set out for the study.
thoracic sAbr safety substudy
This will be done to document the toxicity and feasibility 
of delivering SABR to thoracic metastases with or imme-
diately following radical thoracic RT. Additionally, we will 
be able to assess processes for RT planning and dosim-
etry and have quality assurance (QA) for this group of 
patients.
trIAL dEsIgn And MEthods
SARON is a randomised, multicentre, non-blinded, 
parallel-phase III trial (including trial feasibility and 
thoracic metastatic SABR safety components) for 
patients with oligometastatic (1–3 metastases) NSCLC. 
As already stated, the SARON trial will also include two 
substudies on feasibility and thoracic radiation safety 
(figure 1).
Main trial
Patients will be randomised in a 1:1 ratio to receive either 
standard systemic therapy only (Control Arm) or stan-
dard systemic therapy plus radical RT or SABR to their 
primary tumours (and N1–3 mediastinal nodes where 
present) and SABR/SRS to all the metastatic deposits 
(Investigational Arm) (figure 2).
Allocation to either arm will be decided by a comput-
er-generated randomisation schedule. Patients will be 
stratified by investigational site (hospital), histology 
(adenocarcinoma vs non-adenocarcinoma), nodal stage 
(N0/1 vs N2/3), number of oligometastatic sites (1 vs 2 
or 3), brain metastases (present vs absent).
Due to the different treatment modalities in the study, 
it is not possible to blind the patient or the physician to 
the treatment arm.
setting
The trial will be held in the UK with a target of 30 hospi-
tals/cancer centres that are able to give chemotherapy and 
conventional RRT and to provide SABR/SRS (whether 
in their own centre or via referral to another centre). All 
sites giving RT must have QA accreditation, as guided by 
the Radiotherapy Treatment Quality Assurance (RTTQA) 
group of the National Cancer Research Institute (NCRI).
Cancer Research UK & UCL Cancer Trial Centre (UCL 
CTC), acting on behalf of the sponsor UCL, will need to 
ensure all documents and requirements are reviewed and 
approved before activating the trial and sites.
Intervention
In the intervention arm, the patients will receive up to 
another two cycles of the same chemotherapy regime 
as the control arm, followed by RRT within 2–6 weeks 
of day 1 of cycle 4 of chemotherapy. RRT can be deliv-
ered to the primary lung tumour either by conventional 
radiotherapy or SABR, if appropriate, followed by SABR/
SRS to the oligometastatic lesion(s) (figure 3). Main-
tenance chemotherapy is permitted according to local 
practice.
The radiotherapy must be performed by an approved 
site principal investigator who is experienced in 
treating NSCLC. Patients will be planned and treated 
per the SARON RT Planning and Delivery Guidelines 
(online supplementary appendix 1).
safety monitoring
The treating physician will be able to modify or discon-
tinue a patient treatment in either arm for various reasons, 
including perceived harm or toxicities. The treating physi-
cian will have to enter protocol deviations, treatment inter-
ruptions and adverse toxicities in the case report form 
(CRF) and submit it to the UCL CTC.
Figure 1 SARON substudy schema. QA, quality assurance; RT, radiotherapy; SABR, stereotactic ablative radiotherapy.
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All serious adverse events must be reported to UCL 
CTC within 24 hours. The Trial Management Group 
(TMG) and Independent Data Monitoring Committee 
(IDMC) will also adopt a safety monitoring role and will 
review safety issues. Protocols amendments if required 
will be disseminated to all relevant parties.
Initial feasibility substudy
The aims of the feasibility substudy are:
 ► To satisfy the TMG and IDMC that recruitment targets 
are likely to be met for the remainder of the main 
trial.
Figure 2 SARON trial schema. RT, radiotherapy; SABR, stereotactic ablative radiotherapy; SRS, stereotactic radiosurgery. 
Figure 3 Summary of treatment in investigational arm. RT, radiotherapy; SABR, stereotactic ablative  radiotherapy; SRS, 
stereotactic radiosurgery. 
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 ► To determine that the dropout/progression rate in 
the first 50 randomised patients is <30% (ie, for at 
least 50 patients randomised and treated, no more 
than 72 patients have been registered).
 ► That there are no major logistical problems identified 
in the delivery of SABR/SRS.
Trial recruitment will not be suspended during the 
period of feasibility assessment.
As well as the aims above, the feasibility assessment will 
assess:
 ► Practicality of achieving recruitment targets
 – Compare actual recruitment rate with expected re-
cruitment rate.
 – Explore reasons for screening failures/ineligibility.
 – Review drop-off rate between registration and ran-
domisation, including PFS rate following two cycles 
of chemotherapy prior to randomisation.
 ► Logistics of delivering the investigational treatment
 – Practicalities associated with delivering SABR/SRS, 
including:
 – Technicalities in the QA.
 – Access to SABR/SRS for all recruiting centres.
 – Funding.
 ► Potential for contamination, as patients may seek 
SABR/SRS if randomised to the chemotherapy only 
arm.
thoracic sAbr safety substudy
Patients treated with SABR to their thoracic metastases 
(including lung and other intrathoracic metastases, 
that is, thoracic spine and rib) will be monitored more 
closely for toxicity (figure 4). The first 20 patients in 
the experimental arm with thoracic metastases (these 
patients can also have non-thoracic metastases) will 
be treated and followed up for 3 months to assess 
adverse events. Until confirmation of safety, all thoracic 
metastases will be treated in one of approximately 10 
centres, selected by the following criteria:  
 ► Most treatment platforms (ie, manufacturers) are 
represented.
 ► All geographical locations of the UK have 
representation.
 ► An existing active SABR/SRS clinical programme is 
in place.
Eligibility criteria
Inclusion criteria
1. Patient ≥18 years.
2. Histologically or cytologically confirmed NSCLC.
3. Staging with FDG PET-CT whole body scan and MRI 
brain or CT brain scan with IV contrast within 42 days 
prior to registration.
4. ECOG performance status 0–1 at time of registration.
5. Patient presenting with synchronous primary disease 
and oligometastatic disease.
6. Patient is fit to receive four cycles of platinum-based 
doublet chemotherapy, cisplatin or carboplatin, as 
per local guidelines and assessment.
7. Primary tumour and involved nodes included in the 
radical RT volume must be suitable for radical RT 
(either conventional RT or SABR)—conventional RT 
fields do not need to be contiguous.
8. Patient is deemed fit to receive conventional RT and 
SABR/SRS as per local guidelines and assessment.
9. Between one and three metastatic lesions, assessable 
as per RECIST V.1.1 and suitable for SABR and/or 
SRS (only one site of metastases OR the primary tu-
mour needs to be measurable as per RECIST V.1.1).
i. Nodes included in the radical RT volume 
will not count towards the number of sites of 
metastases.
Figure 4 Table detailing number of patients required with ≥grade 3 to action a stoppage on treatment of thoracic metastases 
SABR. RTPN, radiation-induced pneumonitis; SABR, stereotactic ablative radiotherapy. 
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ii. Nodes not treated in the radical RT volume are 
counted as metastases. The patient, though, must 
have stage IV disease. The same RT dose con-
straint eligibility criteria will apply to these nodes 
as to other metastases.
iii. Lower cervical supraclavicular lymph nodes and 
sternal notch nodes are considered N3. Higher 
neck nodes are considered as metastases (IASLC 
2009 criteria).
10. Note: If brain metastasis present, at the time of ran-
domisation, the following parameters must be met 
(table 2).
11. Acceptable lung function for radical lung radio-
therapy as assessed according to local policy. Note: 
Potential thoracic substudy patients will need to com-
plete pulmonary function tests preregistration.
12. No relevant comorbidities, including pulmonary fi-
brosis and connective tissue disorders.
Further inclusion notes
 ► For bone metastases, pre-SABR stabilisation should 
be considered as clinically appropriate. This does not 
exclude the patient from the study.
 ► For patients with brain metastases, there must be 
another metastatic lesion at another site to be eligible 
for the study (sum of intracranial and extracranial 
metastases must be ≤3), as patients with brain only 
metastases would naturally be offered SRS/surgery to 
their intracranial disease in accordance with the 
published commissioning criteria for SRS set by NHS 
England.
 ► Patients with lung cancer and an additional malignant 
nodule are difficult to categorise, and the current stage 
classification rules are unclear. Such patients should 
be evaluated by the local multidisciplinary team to 
determine whether the additional lesion represents a 
second primary lung cancer or an additional tumour 
nodule corresponding to the dominant cancer. The 
SARON TMG will accept local MDM decisions on this 
and will aim to centrally review all baseline PET-CT, 
chest/abdomen CT scans (if performed) and brain 
MRI scans.
Exclusion criteria
1. Patient has had palliative radiotherapy to any tumour 
site prior to registration or requires palliative radio-
therapy prior to randomisation.
2. Presence of EGFR or ALK/ROS-1 mutation (EGFR 
and ALK/ROS-1 testing is only mandatory for pa-
tients with adenocarcinoma).
3. One or more metastases previously treated with al-
ternative ablative treatment, for example, RFA or 
surgery.
4. Patient has received any previous treatment for this 
NSCLC malignancy.
5. Patients who present with brain metastasis only and 
no sites of extracranial metastatic disease, that is, the 
presence of more than two brain metastases is an ex-
clusion criterion.
6. Metastasis in sites where normal radiotherapy con-
straints cannot be met.
7. Brain metastasis within the brainstem.
8. Patients who have more than three metastases prior 
to trial registration.
9. Primary tumour or metastases causing direct invasion 
or high clinical suspicion of direct invasion of the 
wall of a major blood vessel.
10. Malignant pleural or pericardial effusion.
11. Patients with bilateral adrenal metastases.
12. History of prior malignant tumour likely to interfere 
with the protocol treatment or comparisons, unless 
the patient has been without evidence of disease for 
at least 3 years or the tumour was a non-melanoma 
skin tumour or early cervical cancer.
13. Women who are pregnant or breast feeding.
14. Stage III disease even with extensive nodal disease 
(ie, N3 nodal disease but no distant metastases).
15. Leptomeningeal disease.
Eligibility criteria for randomisation
Following cycle 2 of chemotherapy, patients must meet 
the following eligibility criteria for randomisation:
 ► No disease progression on postcycle 2 CT (as per 
RECIST V.1.1)
 – Patients who cannot be randomised, only progres-
sion and OS data will be collected for these patients.
 ► Patients with no or less visible metastases following 
two cycles of chemotherapy are still eligible for 
randomisation
 – If randomised to the investigational arm, these pa-
tients will receive SABR/SRS to visible and SABR/
SRS on relapse of existing metastases.
 – Patients who experience progression with new me-
tastases are not eligible for randomisation or for 
trial treatment.
 ► Patients with complete response of the lung primary 
following two cycles of chemotherapy are eligible for 
randomisation. If randomised to the Investigational 
Arm, these patients will still receive conventional 
RT to the site of the original primary tumour per 
protocol.
 ► ECOG Performance Status 0–2.
 ► Continued suitability for trial treatment as deemed by 
the treating clinician.
Table 2 Acceptable brain metastases diameters
Largest lesion diameter
Second metastasis 
diameter
3 cm ≤2 cm
2.8 cm ≤2.4 cm
2.6 cm ≤2.6 cm
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trIAL EndpoInts
Main trial
Primary endpoint
 ► OS: Measured from date of randomisation until date 
of death from any cause.
Secondary endpoints
 ► PFS: Time from randomisation until progression or 
death from any cause. Progression will be assessed 
using RECIST V.1.1.
 ► LC of primary and all metastases: This refers to 
tumours present at randomisation. Assessed as 
progression at one or more of these tumour sites.
 ► New distant metastasis-free survival: Time from rando-
misation until presence of new distant metastasis (ie, 
the emergence of tumour on imaging at anatomical 
sites where cancer was not present at the time of diag-
nosis) or death from any cause.
 ► Quality of life: As measured by EORTC QLQ-C3034 
and LC13.35
 ► Adverse events, assessed using CTCAE V.4.03, and dose 
delays, reduction and compliance to trial treatment.
Feasibility substudy
Primary endpoint
 ► Recruitment rate, logistical challenges, contamina-
tion, as patients may seek SABR/SRS outside the trial 
if randomised to the chemotherapy only Arm.
thoracic sAbr safety substudy
Primary endpoint
 ► Grade 3–5 radiation-induced pneumonitis (per 
CTCAE V.4.03) up until 3 months’ post-thoracic 
SABR.
Secondary endpoint
 ► Other grade 3–5 RT-related toxicities (per CTCAE 
V.4.03).
pArtICIpAnt rECruItMEnt And tIMELInE
sample size and study duration
In total, 340 patients are required (170 per arm) to 
detect an improvement in median survival from 9.9 
to 14.3 months, that is, a HR of at least 0.69, with a 
two-sided 5% alpha and 85% power and a 10% dropout 
rate.
Prior to study initiation, a survey was sent to all UK 
radiotherapy centres on their SABR/SRS practices. At 
least 26 centres replied with an average of 4.6 suitable 
study patients in the previous 6 months. Assuming only 
half of this amount would satisfy the eligibility criteria, 
this would equate to around 120 patients. We thus expect 
that the trial will take around 3 years to accrue. We hope 
to include more than 30 centres in our study in improve 
on trial participation. Nevertheless, an early feasibility 
study will be conducted after the first 50 patients. The 
study opened August 2016.
recruitment and consent
Patients will be identified through MDT meetings and 
clinic appointments. At the first consult, if all eligibility 
criteria are fulfilled, the team will introduce the trial and 
provide the patient information sheet (detailing ratio-
nale, trial design and risks involved) along with the rele-
vant contact information. Participants will have at least 
24 hours to consider participation. Consent will have to 
be obtained before collection of baseline tumour and 
demographic data and the QoL survey. Patients can with-
draw at any stage of the trial.
After the second chemotherapy cycle, a CT scan will 
be performed. If prerandomisation eligibility criteria are 
fulfilled, the patient will be randomised. At this stage, 
patients who are unable to fulfil the criteria will be with-
drawn from the study and only progression and OS data 
will be collected.
timeline
During the treatment, all recruitment patients will be 
followed up with a blood test and physical examination 
before each chemotherapy treatment cycle. Patients in 
the interventional arm will have fortnightly reviews if they 
need conventional RT and weekly reviews when they have 
SABR/SRS.
On completion of fourth cycle of chemotherapy, an 
assessment will be done by the treating physician every 
month for the first 3 months, then 3 monthly until 2 
years, then 6 monthly until 3 years postchemotherapy. 
During each scheduled visit, the patient will be assessed 
for disease status, performance status, adverse events and 
QoL questionnaire. A CT scan will be required at 3, 6, 
12, 18, 24 and 36 months postchemotherapy (follow-up 
schedule in online supplementary appendix 2).
Patients in the Thoracic SABR Safety substudy will 
need lung function test at 12 and 24 months follow-up 
visits. Additionally, they will have fortnightly reviews for 
the 1st month after radiotherapy and an additional visit 3 
months after radiotherapy.
Patient participation will be completed at death, study 
withdrawal or after 3 years of follow-up.
dAtA MAnAgEMEnt And AnALysIs
data management
Each participant is assigned a trial number by UCL CTC. 
The patient data including CRFs, supporting documents 
(eg, CT scan images, pathology reports) will be submitted 
to UCL CTC without any patient-specific identifiers to 
maintain confidentiality. To avoid missing data, forms 
are checked onsite before submission to UCL CTC. UCL 
CTC will check data for legibility, completeness, accuracy 
and consistency. Query reports will be sent to the data 
contact at site for checks and rectification.
Patients, who discontinue treatment for any reason, 
should be kept on trial for purpose of follow-up and data 
analysis. In patients lost to follow-up, every effort should 
9Conibear J, et al. BMJ Open 2018;8:e020690. doi:10.1136/bmjopen-2017-020690
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be made by the site to contact the GP for information on 
patient status.
All trial-related documents will be archived centrally in 
a secure place for a minimum of 5 years at the end of the 
trial.
Analysis
The data will be analysed on completion of the study. 
Analysis of primary and secondary endpoints will be 
performed on an intention-to-treat population. The OS 
will also be conducted on per-protocol basis. Survival 
endpoints will be assessed using Cox proportional 
hazards models to estimate HRs and Cox regression anal-
ysis to adjust for effect on stratification factors. Missing 
data will be censored at the date they were last known 
to be alive. For all tests, we will use two-sided p values 
with 5% level of significance. QoL data will be analysed 
using mixed effects repeated measured measures model 
and reported by each domain. Adverse events (grade 3–5 
CTCAE V.4.03 events) will be compared between groups 
using χ² of Fisher’s exact test for all patients who received 
any trial treatment.
thoracic sAbr safety substudy analysis
After the initial 20 patients with thoracic metastases 
have been treated and monitored for adverse events. If 
the data show evidence that the true rate of grade 3–5 
pneumonitis related to RT is above 30%, the IDMC may 
consider suspending the treatment of thoracic metastases 
with SABR. If incidence is below 30%, the treatment is 
safe to continue. If inconclusive (ie, 95% the CI of events 
crosses 30%) the substudy will continue for another 10 
patients until a conclusion can be drawn (figure 4).
EthICs And dIssEMInAtIon
Version 1.0 of the protocol was approved by West 
Midlands, Coventry & Warwickshire Research Ethics 
Committee (Registration 15/WM/0392) on 7 December 
2015. All participants will be given a SARON trial patient 
information sheet and will be required to give written 
informed consent. The SARON trial is supported by 
Cancer Research UK (C13530/A18015) and sponsored 
by UCL and coordinated by UCL CTC. Results will be 
submitted for presentation at local and international 
medical conference and expected to be published in a 
peer-reviewed journal.
dIsCussIon
There is growing evidence supporting the safety of 
SABR/SRS, its effect on LC and a possible impact on OS 
to warrant a randomised phase III trial. The key ques-
tion regarding the successful completion of such a trial 
relates to its feasibility, which will be governed by patient 
numbers and access to appropriate SABR/SRS treatment. 
There are also no definitive data yet on the toxicity of 
SABR/SRS in the specific context of thoracic SABR with 
radical RT to the primary tumour and mediastinal lymph 
nodes. SARON is an important study, as it will test the 
impact of radical RT and SABR/SRS on OS in oligometa-
static NSCLC with an early evaluation of overall feasibility 
and toxicity for thoracic metastases. The study is currently 
recruiting; the study opened to recruitment in the UK 
on 11 August 2016 and the first patient was enrolled 19 
August 2016.
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